|
C9ORF64 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.71771494197992E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.02090003117894E-10 |
| Normal-vs-Stage2 |
3.83760000000066E-06 |
| Normal-vs-Stage3 |
2.32340036099288E-10 |
| Normal-vs-Stage4 |
2.19024798298051E-12 |
| Stage1-vs-Stage2 |
9.269200E-01 |
| Stage1-vs-Stage3 |
3.480400E-01 |
| Stage1-vs-Stage4 |
5.761300E-03 |
| Stage2-vs-Stage3 |
4.968000E-01 |
| Stage2-vs-Stage4 |
3.540500E-02 |
| Stage3-vs-Stage4 |
6.047900E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.80757664181419E-13 |
| Normal-vs-AfricanAmerican |
1.822730E-04 |
| Normal-vs-Asian |
1.27999999488537E-08 |
| Caucasian-vs-AfricanAmerican |
3.943600E-01 |
| Caucasian-vs-Asian |
7.039400E-01 |
| AfricanAmerican-vs-Asian |
3.199000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.60359999723525E-08 |
| Normal-vs-Female |
1.92867943837882E-12 |
| Male-vs-Female |
5.781800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.22279980480289E-10 |
| Normal-vs-Age(41-60Yrs) |
3.90980026132581E-10 |
| Normal-vs-Age(61-80Yrs) |
2.89830381916545E-11 |
| Normal-vs-Age(81-100Yrs) |
1.515790E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.030000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.388800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.212200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.546440E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.582000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.245600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.712280E-02 |
| Classical-VS-Follicular |
3.874600E-01 |
| Classical-VS-Other |
5.776000E-01 |
| Classical-VS-Normal |
8.8304030754216E-11 |
| Tall-VS-Follicular |
2.010400E-01 |
| Tall-VS-Other |
7.428400E-01 |
| Tall-VS-Normal |
1.71930003567411E-09 |
| Follicular-VS-Other |
8.505400E-01 |
| Follicular-VS-Normal |
3.75619999548604E-08 |
| Other-VS-Normal |
3.377300E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.65869573421196E-11 |
| Normal-vs-N1 |
3.85058651630743E-12 |
| N0-vs-N1 |
1.301520E-02 |
|
|
